Results · Apr-Jun 2026 · filed 13 Aug 2026
Brawn Biotech Q1 FY27 results
Sales grew 5% to ₹6.1 crore from ₹5.8 crore in Apr-Jun 2025.
Operating profit fell 74% to ₹0.05 crore, an operating margin of 0.8% (down 2.3 points from a year ago).
Net profit fell 35% to ₹0.15 crore from ₹0.24 crore in Apr-Jun 2025.
Against Jan-Mar 2026: sales +208%, net profit −74%.
Apr-Jun 2026 vs a year ago
| ₹ crore | Apr-Jun 2026 | Apr-Jun 2025 | Change |
|---|---|---|---|
| Sales | 6.1 | 5.8 | +5% |
| Operating profit (EBITDA) | 0.0 | 0.2 | −74% |
| Operating margin | 0.8% | 3.0% | −2.3 pts |
| Net profit | 0.2 | 0.2 | −35% |
Standalone figures. Margins & ratios change in percentage points (pts).
The last 7 quarters
Filings that week
- 14 Aug 2026Announcement under Regulation 30 (LODR)-Newspaper Publication
- 13 Aug 2026Outcome Of Board Meeting Held On August 13, 2026 To Consider And Approve, Inter-Alia, Un-Audited Financial Results Of The Company For Quarter Ended June 30, 202
- 13 Aug 2026Board Meeting Outcome for Outcome Of Board Meeting Held On August 13, 2026 To Consider And Approve, Inter-Alia, Un-Audited Financial Results Of The Company For
From the company's results filed on BSE (Standalone). Business numbers only. Education & analysis, not investment advice or a recommendation.